Inoviq Ltd FY26 Preliminary Financial Report
Key points
- FY26 revenue: $432,047 (down 21.1%)
- Net loss after tax: $7,505,123 (up 8.3%)
- No dividends declared for FY26
- EXO-OC ovarian cancer test validation study failed due to sample issues
- FY27 focus: EXO-OC validation, CAR-exosome therapeutics, EXO-NET growth
Full summary
Inoviq Ltd's preliminary financial report for FY26 shows a 21.1% decline in revenue to $432,047 and an 8.3% increase in net loss to $7,505,123. The company did not declare any dividends. The expanded clinical study for the EXO-OC ovarian cancer test failed due to poor sample quality from biobank sources. Despite the setback, Inoviq remains committed to its exosome technology platform and is focused on validating EXO-OC, advancing CAR-exosome therapeutics, and growing its EXO-NET business in FY27.
Guidance
FY26 revenue: $432,047, Net loss: $7,505,123, Cash: $9.4 million
Outlook
In FY27, Inoviq plans to complete EXO-OC validation, progress EXO-OC toward US LDT commercialization, advance CAR-exosome therapeutics, grow EXO-NET revenues, and maintain disciplined capital allocation.
Summary generated by a large language model. Please interpret with care.